| |
| |
|
| Insider
Information: |
Gill David N |
| Relationship: |
Director |
| City: |
Knoxville |
| State: |
TN |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
9 |
|
| Direct
Shares |
145,596 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$1,375,592 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
145,596 |
|
|
| Total
Value |
$1,375,592 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
2
|
|
Stock
price went up :
|
1
|
0
|
| Stock
price went down : |
0
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
1.0
|
-2.0
|
| Percentage
Gain/Loss : |
 31.5%
|
 -62.4%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Nxstage Medical, Inc. |
NXTM |
SVP & CFO |
2006-05-10 |
7,442 |
2006-05-10 |
0 |
Premium* |
|
|
Lemaitre Vascular Inc |
LMAT |
Director |
2007-05-16 |
6,805 |
2006-10-31 |
0 |
Premium* |
|
|
Endochoice Holdings, Inc. |
GI |
President and CFO |
2016-11-22 |
0 |
2016-11-22 |
0 |
Premium* |
|
|
Ocugen Ord Shs |
OCGN |
Director |
2017-08-16 |
14,000 |
2016-12-09 |
0 |
Premium* |
|
|
Melinta Therapeutics, Inc |
MLNT |
Director |
2018-05-25 |
6,000 |
2017-01-03 |
0 |
Premium* |
|
|
Strata Skin Sciences Inc |
SSKN |
|
2019-11-22 |
64,694 |
2018-06-08 |
0 |
Premium* |
|
|
Evolus Inc |
EOLS |
Director |
2024-02-07 |
44,325 |
2018-12-14 |
0 |
Premium* |
|
|
Strongbridge Biopharma Plc |
SBBP |
Director |
2021-10-05 |
0 |
2019-09-03 |
0 |
Premium* |
|
|
Y-Mabs Therapeutics Inc |
YMAB |
Director |
2023-06-08 |
2,330 |
2020-11-03 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
45 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| NXTM |
Nxstage Medical, Inc. |
SVP & CFO |
• – – |
2006-05-10 |
4 |
A |
$0.00 |
$0 |
D/D |
7,422 |
7,442 |
|
- |
|
| LMAT |
Lemaitre Vascular Inc |
Director |
– • – |
2006-10-31 |
4 |
B |
$6.05 |
$12,100 |
D/D |
2,000 |
2,000 |
2.39 |
- |
|
| LMAT |
Lemaitre Vascular Inc |
Director |
– • – |
2006-12-22 |
4 |
A |
$0.00 |
$0 |
D/D |
2,805 |
4,805 |
0 |
- |
|
| LMAT |
Lemaitre Vascular Inc |
Director |
– • – |
2007-05-09 |
4 |
B |
$6.25 |
$6,250 |
D/D |
1,000 |
5,805 |
2.39 |
- |
|
| LMAT |
Lemaitre Vascular Inc |
Director |
– • – |
2007-05-15 |
4 |
B |
$6.03 |
$1,206 |
D/D |
200 |
6,005 |
2.31 |
- |
|
| LMAT |
Lemaitre Vascular Inc |
Director |
– • – |
2007-05-16 |
4 |
B |
$6.05 |
$4,840 |
D/D |
800 |
6,805 |
2.31 |
- |
|
| GI |
Endochoice Holdings, Inc. |
See remarks.Officer |
• – – |
2015-06-05 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
79,224 |
|
- |
|
| GI |
Endochoice Holdings, Inc. |
See remarks.Officer |
• – – |
2015-06-05 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
9,155 |
|
- |
|
| GI |
Endochoice Holdings, Inc. |
Chief Financial Officer |
• – – |
2015-08-14 |
4 |
A |
$0.00 |
$0 |
D/D |
53,825 |
133,049 |
0 |
- |
|
| GI |
Endochoice Holdings, Inc. |
Chief Financial Officer |
• – – |
2016-03-07 |
4 |
B |
$4.77 |
$23,850 |
I/I |
5,000 |
23,130 |
1.99 |
- |
|
| GI |
Endochoice Holdings, Inc. |
Chief Financial Officer |
• – – |
2016-03-10 |
4 |
B |
$4.70 |
$9,400 |
I/I |
2,000 |
25,130 |
1.99 |
- |
|
| GI |
Endochoice Holdings, Inc. |
President and CFO |
• – – |
2016-03-29 |
4 |
A |
$0.00 |
$0 |
D/D |
14,826 |
137,405 |
0 |
- |
|
| GI |
Endochoice Holdings, Inc. |
President and CFO |
• – – |
2016-11-22 |
4 |
D |
$8.00 |
$1,003,560 |
D/D |
(125,445) |
0 |
0 |
- |
|
| GI |
Endochoice Holdings, Inc. |
President and CFO |
• – – |
2016-11-22 |
4 |
D |
$8.00 |
$308,680 |
I/I |
(38,585) |
0 |
0 |
- |
|
| OCGN |
Ocugen Ord Shs |
Director |
– • – |
2016-12-09 |
4 |
B |
$1.92 |
$9,600 |
D/D |
5,000 |
5,000 |
2.39 |
- |
|
| OCGN |
Ocugen Ord Shs |
Director |
– • – |
2016-12-15 |
4 |
B |
$1.65 |
$4,950 |
D/D |
3,000 |
8,000 |
2.31 |
- |
|
| MLNT |
Melinta Therapeutics, Inc |
Director |
– • – |
2017-01-03 |
4 |
B |
$2.94 |
$14,720 |
D/D |
5,000 |
5,000 |
2.39 |
- |
|
| OCGN |
Ocugen Ord Shs |
Director |
– • – |
2017-05-16 |
4 |
B |
$1.68 |
$5,040 |
D/D |
3,000 |
11,000 |
2.39 |
- |
|
| OCGN |
Ocugen Ord Shs |
Director |
– • – |
2017-08-16 |
4 |
B |
$1.81 |
$5,439 |
D/D |
3,000 |
14,000 |
2.39 |
- |
|
| MLNT |
Melinta Therapeutics, Inc |
Director |
– • – |
2018-05-25 |
4 |
B |
$6.09 |
$30,450 |
D/D |
5,000 |
6,000 |
2.39 |
- |
|
| SSKN |
Strata Skin Sciences Inc |
Director |
– • – |
2018-06-08 |
4/A |
A |
$0.00 |
$0 |
D/D |
31,401 |
46,401 |
0 |
- |
|
| EOLS |
Evolus Inc |
Director |
– • – |
2018-12-14 |
4 |
B |
$12.77 |
$38,300 |
D/D |
3,000 |
3,000 |
2.39 |
- |
|
| EOLS |
Evolus Inc |
Director |
– • – |
2019-06-13 |
4 |
B |
$13.65 |
$27,300 |
D/D |
2,000 |
5,000 |
2.39 |
- |
|
| SBBP |
Strongbridge Biopharma Pl... |
Director |
– • – |
2019-09-03 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
50,000 |
0 |
- |
|
| SSKN |
Strata Skin Sciences Inc |
|
• • – |
2019-11-22 |
4 |
A |
$0.00 |
$0 |
D/D |
18,293 |
64,694 |
0 |
- |
|
45 Records found
|
|
Page 1 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
